Published in AIDS Weekly, November 24th, 2003
Based on the encouraging results, Samaritan is in the process of developing a phase III clinical study regimen designed to attack the virus in new ways.
Dr. Janet Greeson, chief executive officer of Samaritan Pharmaceuticals, stated, "While AIDS related deaths have declined, the number of people living with HIV still continues to grow. We are attempting to design a phase III...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.